The American Society for Hematology (ASH) released its first guidelines for stem cell transplantation for sickle cell disease. The guidelines weigh the risks and benefits of transplantation compared to disease-modifying treatments or potentially curative therapy in development. The guidelines are published in American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation (Kanter, et al. Blood Adv . 2021;doi:10.1182/bloodadvances.2021004394C).
Key recommendations in the guidelines include:
- HSCT should be considered the standard of care for patients who have had or have a high risk for stroke, as well as for all patients with neurologic injury who have a matched-related sibling donor.
- Patients with frequent pain and those with recurrent episodes of acute chest syndrome should use related matched allogeneic transplantation rather than standard of care.
- Patients with an indication for HSCT who lack a matched sibling donor should use transplants from alternative donors in the context of a clinical trial.